StageBio’s very own Dr. Thomas Lemarchand will join his colleagues at the 63rd annual American Society of Hematology (ASH) meeting to present their findings on the newly designated Lambda Myeloma Antigen (LMA). During the presentation, which is titled, “A Novel B Cell Antigen Designated Lambda Myeloma Antigen (LMA) Has Been Identified Using Two Fully Human Monoclonal Antibodies (Mabs) That Bind to Similar Epitopes on Plasma Cells from Patients with Plasma Cell Dyscrasias,” Dr. Lemarchand and his team will detail the methods they used to detect the LMA, including flow cytometry on key cell lines and immunohisto-chemistry on normal and pathologic human frozen tissues and results, with what this could mean for myeloma treatment and understanding the pathogenesis.

When: Saturday, December 11, 2021
Time: 5:30 PM – 7:30 PM
Where: The ASH Annual Meeting and Expo (Atlanta, Georgia)
The full poster will be available after December 11. You can learn more about the ASH
Annual Meeting and Expo here.